Research background
Semaglutide is a synthetic analog of human glucagon-like peptide-1 in which two residue substitutions and a C-18 diacid side chain markedly slow enzymatic clearance. It became a reference incretin analog in metabolic literature because its extended plasma residence allows week-scale pharmacodynamic modelling that native GLP-1, with a half-life measured in minutes, cannot support.


